Jade Biosciences’ (JBIO) Buy Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Jade Biosciences (NASDAQ:JBIO) in a report published on Tuesday,Benzinga reports. The firm currently has a $77.00 price target on the stock.

Other equities analysts have also issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Jade Biosciences in a research note on Friday, September 11th. Wedbush restated an “outperform” rating and set a $47.00 price target on shares of Jade Biosciences in a report on Thursday, October 1st. Wall Street Zen downgraded shares of Jade Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 12th. Jefferies Financial Group reiterated a “buy” rating and issued a $48.00 price objective on shares of Jade Biosciences in a research note on Tuesday, August 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of Jade Biosciences in a research report on Thursday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Jade Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $51.75.

Jade Biosciences Stock Down 2.4%

JBIO stock opened at $14.24 on Tuesday. The company has a fifty day moving average price of $16.63 and a 200-day moving average price of $18.14. Jade Biosciences has a 52-week low of $8.36 and a 52-week high of $28.00.

Jade Biosciences (NASDAQ:JBIO) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). On average, equities research analysts anticipate that Jade Biosciences will post -2.89 earnings per share for the current fiscal year.

Institutional Trading of Jade Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Profund Advisors LLC raised its position in Jade Biosciences by 21.5% in the third quarter. Profund Advisors LLC now owns 26,008 shares of the company’s stock worth $365,000 after acquiring an additional 4,596 shares during the period. Engineers Gate Manager LP purchased a new position in Jade Biosciences in the second quarter valued at about $503,000. Maven Securities LTD bought a new position in shares of Jade Biosciences during the 2nd quarter valued at approximately $1,111,000. Squarepoint Ops LLC grew its position in shares of Jade Biosciences by 22.0% during the 2nd quarter. Squarepoint Ops LLC now owns 54,456 shares of the company’s stock valued at $1,210,000 after acquiring an additional 9,806 shares during the period. Finally, Corient Private Wealth LP bought a new position in shares of Jade Biosciences during the 2nd quarter valued at approximately $1,367,000.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for autoimmune and other immune-mediated diseases. The company is building a pipeline of antibody-based therapies designed to modulate the immune system and address significant unmet medical needs.

Jade’s development programs include JDB001, an investigational therapeutic being advanced for potential use in immune-mediated conditions. The company’s product candidates remain in clinical development and have not been approved for commercial use.

Jade Biosciences is headquartered in the United States and conducts its research and development activities through a biotechnology-focused operating model.